Clinical trials: Urologic Disorders
Renal Impairment
Safety and Pharmacokinetics of Fluzoparib in Healthy Subjects and Those With Impaired Kidney Function
The primary objective is to evaluate pharmacokinetics of Fluzoparib and its main metabolite in subjects with impaired kidney function in comparison with healthy subjects, to develop dose recommendations for patients with renal…
- Trial name
- NCT05032235
- Testing
- Fluzoparib
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Autosomal Dominant Polycystic Kidney Disease
ANCHOR Study: A Study to Assess the Safety and Efficacy of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most common genetic cause of kidney disease that causes fluid-filled cysts to develop in the kidneys.
- Trial name
- ANCHOR (NCT06902558)
- Testing
- ABBV-CLS-628
- Where
- 91 sites in United States, Australia and 10 more
- Volunteers
- 240 people
- Sponsor
- Calico Life Sciences LLC
Urinary Incontinence , Stress
Pilot Study of the ARTUS® Artificial Urinary Sphincter on Women
The subjects will be implanted with the ARTUS® medical device and then be followed up to 2 years post-implantation, with the primary endpoints measured at 3-month post-implantation.
- Trial name
- SPHIN-X (NCT07641218)
- Testing
- Artificial Urinary Sphincter ARTUS
- Where
- 2 sites in France
- Volunteers
- 6 people
- Sponsor
- Myopowers Medical Technologies France SAS
Solid Tumor, Breast Tumor
Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors
The purpose of this study is to further evaluate the efficacy and safety of niraparib in patients with locally advanced or metastatic solid tumors and a pathogenic or likely pathogenic tumor PALB2 (tPALB2) mutation.
- Conditions
- Solid Tumor, Breast Tumor, Colon Tumor, Malignant, Lung Tumor
- Trial name
- PAVO (NCT05169437)
- Testing
- Niraparib
- Where
- 80 sites in United States
- Volunteers
- 22 people
- Sponsor
- Tempus AI
Chronic Kidney Disease, Dialysis
A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With Hyperphosphatemia
This is a phase III multi-centre study in three periods: the first period is a phosphate binder washout for 4 weeks, the second period is an open-label, flexible dose titration, the third period is a placebo-controlled withdrawal…
- Conditions
- Chronic Kidney Disease, Dialysis, Hyperphosphatemia
- Trial name
- NCT00506441
- Testing
- MCI-196
- Where
- 39 sites in United States, Puerto Rico
- Volunteers
- 245 people
- Sponsor
- Tanabe Pharma Corporation
Renal Cell Carcinoma
A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)
This is a randomized, Phase 3, double-blind, placebo-controlled study of pazopanib plus abexinostat versus pazopanib plus placebo in patients with locally advanced unresectable or metastatic renal cell carcinoma (RCC).
- Trial name
- NCT03592472
- Testing
- Pazopanib, Abexinostat
- Where
- 38 sites in United States, China and 4 more
- Volunteers
- 413 people
- Sponsor
- Xynomic Pharmaceuticals, Inc.
Renal Impairment
A Study to Evaluate the Effect of Renal Impairment on JNJ-64417184 and Its Two Minor Metabolites JNJ-68294291 and JNJ-65201526 in Adult Participants
The main purpose of this study is to evaluate the pharmacokinetics of JNJ-64417184, JNJ-68294291, and JNJ-65201526 after a single oral dose of JNJ-64417184 in adult participants with various degrees of impaired renal function…
- Trial name
- NCT04426357
- Testing
- JNJ-64417184
- Where
- 2 sites in Germany
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Cancer)
A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors.
This is a multicenter, open-label, randomized (1:1) trial designed to evaluate whether ctDNA-guided interruption of immune-checkpoint inhibitor (ICI) therapy provides comparable survival to standard of care (SoC) continuous ICI…
- Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Carcinoma), NSCLC
- Trial name
- SIGNAL-IO 301 (NCT07689812)
- Testing
- Signatera Genome ultra-sensitive ctDNA blood test
- Volunteers
- 920 people
- Sponsor
- Natera, Inc.
Kidney Cancer
Interleukin-2, Vinblastine, and GM-CSF in Treating Patients With Metastatic Kidney Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interleukin-2 may stimulate a person's white blood cells to kill cancer cells.
- Trial name
- NCT00003181
- Testing
- aldesleukin, sargramostim, vinblastine sulfate
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Hope Cancer Institute, Inc.
Solid Tumor, Adult
A Tissue Collection Study in Patients Who Respond to Immune Checkpoint Inhibitors to Identify Targets of Tumor-Reactive T Cells.
T Cell Receptor-engineered T-cell therapy (TCR T-cell therapy) offers a potentially transformative approach to treating cancer, but is currently limited by the lack of known targets (Maus and June, 2016; Ping et al., 2018).
- Trial name
- NCT05230186
- Testing
- Tumor Biopsy
- Where
- 4 sites in United States
- Volunteers
- 12 people
- Sponsor
- TScan Therapeutics, Inc.
Interstitial Cystitis, Bladder Pain Syndrome
Assessment of Urinary Polymerase Chain Reaction (PCR) and Next Generation Sequencing (NGS) Technology in the Evaluation and Management of Females With Chronic Bladder Pain and Cystitis-like Symptoms
Real-world clinical practice multicenter study to determine the clinical implications of employing PCR/NGS technology to identify and treat potential urinary pathogens in female participants identified with bladder pain and/or…
- Trial name
- NCT05276466
- Testing
- Polymerase Chain Reaction and Next-Generation DNA Sequencing
- Where
- 4 sites in United States
- Volunteers
- 100 people
- Sponsor
- MicroGenDX
Secondary Hyperparathyroidism, End Stage Renal Disease
A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Patients on Dialysis
This 6 month study will assess an investigational medication for patients on dialysis with secondary hyperparathyroidism. The study will look at the effects on parathyroid hormone, calcium and phosphorus levels.
- Trial name
- NCT00042653
- Testing
- AMG 073
- Volunteers
- 380 people
- Sponsor
- Amgen
Carcinoma, Renal Cell
An Open-Label, Non-Comparative, Phase III Study of the Raf-Kinase Inhibitor BAY 43-9006 as a Subsequent to First-Line Therapy in Patients With Advanced Renal Cell Carcinoma
Purpose of the study: The purpose of this study is to make sorafenib available for patients with advanced Renal Cell Carcinoma, who have failed prior systemic therapy for advanced disease (i.e.
- Trial name
- NCT00492986
- Testing
- Nexavar (Sorafenib, BAY43-9006)
- Where
- 33 sites in Belgium, Denmark and 9 more
- Volunteers
- 1,150 people
- Sponsor
- Bayer
Stress Urinary Incontinence
A Phase 2a Study To Evaluate VMB-100 In Females With Stress Urinary Incontinence
The study drug VMB-100 is an mRNA encoding for IGF-1. It is administered by injection into the urethra sphincter, and taken up by the muscle cells.
- Trial name
- NCT06247241
- Testing
- VMB-100
- Sponsor
- Versameb AG
Atypical Hemolytic Uremic Syndrome
Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-Resistant aHUS
The purpose of this study is to determine whether eculizumab is safe and effective in the treatment of adult patients with plasma therapy-resistant Atypical Hemolytic-Uremic Syndrome (aHUS).
- Trial name
- aHUS (NCT00844545)
- Testing
- Eculizumab
- Where
- 17 sites in United States, Austria and 3 more
- Volunteers
- 16 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Renal Insufficiency
The Pharmacokinetic, Safety and Tolerability of Tiotropium in Outpatients With Renal Impairment in Comparison to Healthy Subjects
Study to investigate pharmacokinetics of a single i.v. dose of tiotropium (4.8 mcg) in patients with renal impairment in comparison to healthy subjects.
- Trial name
- NCT02172339
- Testing
- Tiotropium, solution ampoules
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Bladder Cancer
A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT
Phase I/II study: Phase 1 is an open-label, safety study, patients who previously received 3-6 instillations of weekly intravesical Bacillus Calmette-Guerin (BCG) induction therapy (as standard of care) followed by low dose…
- Trial name
- NCT02010203
- Testing
- HS-410, BCG
- Where
- 19 sites in United States
- Volunteers
- 104 people
- Sponsor
- Heat Biologics
Chronic Kidney Disease, Chronic Renal Insufficiency
Growth Hormone Treatment in Infants Aged 1 to 2 Years With Chronic Renal Insufficiency (CRI) and Growth Retardation.
This trial is conducted in Europe. Objective(s): To evaluate the effect of human growth hormone on infants aged 1 to 2 years with chronic renal insufficiency (CRI) and growth retardation despite an adequate dietary intake.
- Trial name
- NCT00184769
- Testing
- somatropin
- Where
- 20 sites in Portugal, Spain
- Volunteers
- 16 people
- Sponsor
- Novo Nordisk A/S
Heart Failure, Kidney Disease
Neck-Worn Monitoring Sensor for - A Study for Monitoring Subjects With Fluid-Management Issues During Dialysis
The study has two objectives based on the intended-use measurements and populations described above. The first objective is to show that relative changes in impedance as measured by the test device (ΔSFI) are strongly correlated…
- Trial name
- NCT02140905
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Baxter Healthcare Corporation
Urinary Tract Infections
Noroxin Efficacy and Safety Trial
To determine the efficacy and safety of Norfloxacin (Noroxin)
- Trial name
- NEST (NCT03506256)
- Testing
- Norfloxacin 400 MG
- Volunteers
- 1,000 people
- Sponsor
- OBS Pakistan